AMENDMENT NO. 1 TO THE COLLABORATION AGREEMENTThe Collaboration Agreement • November 14th, 2005 • Viacell Inc • Services-commercial physical & biological research • New York
AMENDMENT 1 TO THE COLLABORATION AGREEMENT BETWEENThe Collaboration Agreement • September 6th, 2019 • Anixa Biosciences Inc • Services-medical laboratories
The Agreement described above was previously entered into on November 17, 2017 (hereinafter "Effective Date) by and between H. Lee Moffitt Cancer Center and Research Institute, Inc. a non-profit Florida corporation organized pursuant to Section 1004.43, Florida Statutes, whose address is 12902 Magnolia Drive, Tampa, Florida 33612 ("Moffitt") and Certainty Therapeutics, Inc., a corporation duly organized under the laws of Delaware whose address is 3150 Almaden Expressway, Suite 250, San Jose, California 95118 (hereinafter "Company"). Moffitt and Company are hereinafter referred to individually as "Party" and collectively as "Parties."
AMENDMENT NO.1 TO COLLABORATION AGREEMENTThe Collaboration Agreement • August 9th, 2011 • Medivation, Inc. • Pharmaceutical preparations
This Amendment No. 1 to the Collaboration Agreement (this “Amendment”) is entered into and effective as of January 1, 2010 (the “Amendment Effective Date”) by and among MEDIVATION, INC., a Delaware corporation having its principal place of business at 201 Spear Street, 3rd Floor, San Francisco, California 94105, United States, its wholly owned subsidiary Medivation Prostate Therapeutics, Inc., a Delaware corporation having its principal place of business at the same location (such entities, collectively, “Medivation”), ASTELLAS PHARMA INC., a Japanese corporation having a principal office at 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411, Japan (“API”) and its indirect wholly owned subsidiary Astellas US LLC, a Delaware limited liability company having its principal place of business at Three Parkway North, Deerfield, Illinois 60015, United States (“AUS”; collectively with API, “Astellas”). Medivation and Astellas are sometimes referred to herein individually as a “Party” and
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED SECOND AMENDMENT TO THE...The Collaboration Agreement • March 30th, 2021 • BioNTech SE • Biological products, (no disgnostic substances)
This SECOND AMENDMENT (the “Second Amendment”) is made and entered into, effective as of December 6, 2019 (the “Second Amendment Effective Date”), by and between BioNTech RNA Pharmaceuticals GmbH, a limited liability company organized under the laws of Germany (“RNP”) and BioNTech SE, a European stock corporation (“BNT”) (RNP and BNT collectively, “BioNTech”), and Genentech, Inc., a corporation organized under the laws of the State of Delaware (“GNE”) and F. Hoffmann-La Roche Ltd, a corporation organized under the laws of Switzerland (“Roche”) (GNE and Roche, collectively, “Genentech”).
SECOND AMENDMENT TO THE COLLABORATION AGREEMENTThe Collaboration Agreement • March 31st, 2020 • BioNTech SE • Biological products, (no disgnostic substances)
This SECOND AMENDMENT (the “Second Amendment”) is made and entered into, effective as of December 6, 2019 (the “Second Amendment Effective Date”), by and between BioNTech RNA Pharmaceuticals GmbH, a limited liability company organized under the laws of Germany (“RNP”) and BioNTech SE, a European stock corporation (“BNT”) (RNP and BNT collectively, “BioNTech”), and Genentech, Inc., a corporation organized under the laws of the State of Delaware (“GNE”) and F. Hoffmann-La Roche Ltd, a corporation organized under the laws of Switzerland (“Roche”) (GNE and Roche, collectively, “Genentech”).
JOINDER AND THIRD AMENDMENT TO THE COLLABORATION AGREEMENTThe Collaboration Agreement • March 30th, 2021 • BioNTech SE • Biological products, (no disgnostic substances)
This JOINDER AND THIRD AMENDMENT (the “Third Amendment”) is made and entered into, effective as of October 1, 2020 (the “Third Amendment Effective Date”), by and between (1) BioNTech RNA Pharmaceuticals GmbH, a limited liability company organized under the laws of Germany (“RNP”) and BioNTech SE, a European stock corporation (“BNT”) (RNP and BNT collectively, “BioNTech”), (2) Genentech, Inc., a corporation organized under the laws of the State of Delaware (“GNE”) and F. Hoffmann-La Roche Ltd, a corporation organized under the laws of Switzerland (“Roche”) (GNE and Roche, collectively, “Genentech”) and (3) BioNTech Manufacturing GmbH, a German limited liability company having its principal place of business at An der Goldgrube 12, 55131, Germany (“BMG”),
FIRST AMENDMENT TO THE COLLABORATION AGREEMENTThe Collaboration Agreement • March 31st, 2020 • BioNTech SE • Biological products, (no disgnostic substances)
is made and entered into, effective as of June 1, 2018 ("Amendment Effective Date"), by and between BioNTech RNA Pharmaceuticals GmbH, a limited liability company organized under the laws of Germany ("RNP") and BioNTech AG, a stock corporation organized under the laws of Germany ("BNT") (RNP and BNT collectively, "BioNTech"), and Genentech, Inc., a corporation organized under the laws of the State of Delaware ("GNE") and F. Hoffmann-La Roche Ltd, a corporation organized under the laws of Switzerland ("Roche") (GNE and Roche, collectively, "Genentech"). BioNTech and Genentech are sometimes referred to herein individually as a "Party" and collectively as the "Parties ."
AMENDMENT No. 2 TO THE COLLABORATION AGREEMENT FOR PRODUCTION, BROADCASTING AND RECORDING OF AUDIO-VISUAL AND SOUND RECORD OF THE EVENT RIGHTEOUS AMONG THE NATIONS CONCLUDED IN ACCORDANCE WITH §269 PAR 2 OF THE COMMERCIAL CODE AND RELEVANT PROVISIONS...The Collaboration Agreement • December 31st, 2021
AMENDMENT IVThe Collaboration Agreement • November 20th, 2012 • Ceres, Inc. • Agricultural production-crops
to the Collaboration Agreement effective as of November 15, 2007 between Ceres, Inc. and Institute of Crop Sciences of the Chinese Academy of Agricultural Sciences, as amended (the “Agreement”).
AMENDMENT No. 2 TO THE COLLABORATION AGREEMENTThe Collaboration Agreement • May 4th, 2018 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 2 TO THE COLLABORATION AGREEMENT (this “Collaboration Amendment” or this “Agreement”), entered into as of January 6, 2018 (the “Execution Date”), is entered into by and between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Alnylam”) and Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (“Genzyme”).
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, ANDThe Collaboration Agreement • March 30th, 2021 • BioNTech SE • Biological products, (no disgnostic substances)
This FOURTH AMENDMENT (the “Fourth Amendment”) is made and entered into, effective as of October 26, 2020 (the “Fourth Amendment Effective Date”), by and between BioNTech RNA Pharmaceuticals GmbH, a limited liability company organized under the laws of Germany (“RNP”), BioNTech Manufacturing GmbH, a limited liability company organized under the laws of Germany (“BMG”) and BioNTech SE, a European stock corporation (“BNT”) (RNP, BMG and BNT collectively, “BioNTech”), and Genentech, Inc., a corporation organized under the laws of the State of Delaware (“GNE”) and F. Hoffmann-La Roche Ltd, a corporation organized under the laws of Switzerland (“Roche”) (GNE and Roche, collectively, “Genentech”).
ContractThe Collaboration Agreement • February 25th, 2010 • Great Plains Energy Inc • Electric services
Second Amendment to the Collaboration AgreementThe Collaboration Agreement • August 5th, 2010 • Exelixis Inc • Services-commercial physical & biological research
This second amendment (the “Second Amendment”) to the Collaboration Agreement dated December 22, 2006 (the “Agreement”) between Exelixis, Inc. (“Exelixis”) and Genentech, Inc. (“Genentech”) is made and entered into by Exelixis and Genentech effective as of April 30, 2010 (the “Second Amendment Effective Date”). All capitalized terms not expressly defined in this Second Amendment shall have the meaning assigned to them in the Agreement.
DATED 2016The Collaboration Agreement • September 27th, 2020
AMENDMENT IIIThe Collaboration Agreement • July 12th, 2012 • Ceres, Inc. • Agricultural production-crops
to the Collaboration Agreement effective as of November 15, 2007 between Ceres, Inc. and Institute of Crop Sciences of the Chinese Academy of Agricultural Sciences, as amended (the “Agreement”).
Second Amendment to the Collaboration Agreement Dated June 11, 1998The Collaboration Agreement • November 3rd, 2010 • Gen Probe Inc • Surgical & medical instruments & apparatus
This Second Amendment to the Collaboration Agreement is made and entered into as of July 1, 2009 (the “Effective Date”), by and between Siemens Healthcare Diagnostics Inc. (“Siemens”), a California corporation and the successor-in-interest to Bayer HealthCare LLC (“Bayer”), which was successor-in-interest to Chiron Diagnostics Corporation (“CDC”), and having a principle place of business at 1717 Deerfield Road, Deerfield, Illinois, and Gen-Probe Incorporated (“Gen-Probe”), a Delaware corporation whose principal place of business is 10210 Genetic Center Drive, San Diego, California. Each of Siemens and Gen-Probe are sometimes referred to herein, individually, as a “Party” and, together, as the “Parties.”
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED SECOND AMENDMENT TO THE...The Collaboration Agreement • January 27th, 2020 • BioNTech SE • Biological products, (no disgnostic substances)
This SECOND AMENDMENT (the “Second Amendment”) is made and entered into, effective as of December 6, 2019 (the “Second Amendment Effective Date”), by and between BioNTech RNA Pharmaceuticals GmbH, a limited liability company organized under the laws of Germany (“RNP”) and BioNTech SE, a European stock corporation (“BNT”) (RNP and BNT collectively, “BioNTech”), and Genentech, Inc., a corporation organized under the laws of the State of Delaware (“GNE”) and F. Hoffmann-La Roche Ltd, a corporation organized under the laws of Switzerland (“Roche”) (GNE and Roche, collectively, “Genentech”).
EXHIBIT 10.120 AMENDMENT TO THE COLLABORATION AGREEMENTThe Collaboration Agreement • March 8th, 2000 • Axys Pharmecueticals Inc • Pharmaceutical preparations • New York
* ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. SECOND...The Collaboration Agreement • November 15th, 2002 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)
This Second Amendment to the Collaboration Agreement (“Second Amendment”) is made and entered into on September 16, 2002 (the “Amendment Date”), by and between ONYX PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 3031 Research Drive, Richmond, California 94806 (“Onyx”) and WARNER-LAMBERT COMPANY, a Delaware corporation and a wholly-owned subsidiary of Pfizer Inc. having a place of business at 2800 Plymouth Road, Ann Arbor, MI 48105 (“Warner”).
SECOND AMENDMENT TO THE COLLABORATION AGREEMENTThe Collaboration Agreement • August 10th, 2009 • Medicis Pharmaceutical Corp • Pharmaceutical preparations
This Second Amendment (“Second Amendment”) to the Collaboration Agreement is effective as of the Second Amendment Effective Date (as set forth in Section 4 of this Second Amendment), by and between UCYCLYD PHARMA, INC., a Maryland corporation, with its principal place of business at 7720 North Dobson Road, Scottsdale, AZ 85256 (“Ucyclyd”) and HYPERION THERAPEUTICS, INC., a Delaware corporation, with its principal place of business at 601 Gateway Blvd., Suite 200, South San Francisco, CA 94080 (hereunder referred to as “Hyperion”). Ucyclyd and Hyperion are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Confidential AMENDMENT NO. 3 TO THE COLLABORATION AGREEMENTThe Collaboration Agreement • August 6th, 2019 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 3 TO THE COLLABORATION AGREEMENT (this “Agreement”), dated as of April 8, 2019 (the “Amendment No. 3 Effective Date”), is entered into by and between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Alnylam”), and Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (“Genzyme”).
AMENDMENT #1 TO THE COLLABORATION AGREEMENT BETWEEN ONYX PHARMACEUTICALS, INC. AND WARNER-LAMBERT COMPANYThe Collaboration Agreement • November 14th, 2001 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT #1 to the Collaboration Agreement (the “Amendment”) is made and entered into on August 6, 2001 (the “Amendment Date”), by and between ONYX PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 3031 Research Drive, Richmond, California 94806 (“Onyx”), and the Warner-Lambert Company, a Delaware corporation and a wholly-owned subsidiary of Pfizer Inc, having a place of business at 2800 Plymouth Road, Ann Arbor, MI 48105 ("Warner"). Onyx and Warner may be referred to herein individually as a “Party” and collectively as the “Parties.”
